Phaseline

Targets › IDO1

IDO1 (Indoleamine 2,3-dioxygenase 1): drug programs, companies and trials

8 programs from 6 companies in 8 trials: 4 Phase 2, 3 Phase 1, 1 Phase 3; Oncology, Infectious disease; next expected readout Dec 2026.

Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway. Involved in the peripheral immune tolerance, contributing to maintain homeostasis by preventing autoimmunity or immunopathology that would result from uncontrolled and overreacting immune responses. (UniProt, P14902)

Open in Phaseline: the race on IDO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IO BiotechIO102-IO103
Dual peptide antigen cancer vaccine (IDO peptide antigen IO102 and PD-L1 peptide antigen I
IDO1, CD274Phase 3Metastatic MelanomaSep 2027
Memorial Sloan Kettering Cancer CenterEpacadostat
Indoleamine 2,3-dioxygenase inhibitor
IDO1Phase 2SarcomaJan 2027
IO BiotechIO102
IDO1 peptide
IDO1Phase 2MelanomaJan 2027
University Hospital, Basel, Switzerlandindoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor
IDO-1 inhibitor
IDO1Phase 2EBV InfectionsFeb 2027
Memorial Sloan Kettering Cancer CenterLinrodostat (BMS-986205)
Indoleamine 2,3-dioxygenase inhibitor
IDO1Phase 2Endometrial AdenocarcinomaSep 2027
University of California, DavisIO102-IO103 Peptide Vaccine
PD-L1/IDO peptide vaccine activating T-cells against tumor and immune suppressive cells
CD274, IDO1Phase 1High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaDec 2026
Northwestern UniversityLinrodostat (BMS-986205)
Indoleamine 2,3-dioxygenase inhibitor
IDO1Phase 1GlioblastomaFeb 2027
Washington University School of MedicineEpacadostat (INCB024360)
Indoleamine 2,3-dioxygenase inhibitor
IDO1Phase 1Rectal CancerJul 2027

Conditions

Sarcoma (1) EBV Infections (1) Endometrial Adenocarcinoma (1) Glioblastoma (1) High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma (1) Metastatic Melanoma (1) Melanoma (1) Rectal Cancer (1)

Modalities

mixed (6), protein or peptide (1), small molecule (1)

Companies

Memorial Sloan Kettering Cancer Center (2) IO Biotech (2) University Hospital, Basel, Switzerland (1) Northwestern University (1) University of California, Davis (1) Washington University School of Medicine (1)

Related targets

CD274 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.